BEAM

Beam Therapeutics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↑ 7/10
  • Value↓ 0/10
Beam Therapeutics sales and earnings growth
BEAM Growth
Good
  • Revenue Y/Y↑ 111.95%
  • EPS Y/Y↑ 89.13%
  • FCF Y/Y↓ -6.34%
Beam Therapeutics gross and profit margin trends
BEAM Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -39.70%
  • ROIC 5Y↓ -24.63%
Beam Therapeutics net debt vs free cash flow
BEAM Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Beam Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks